



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Fumihiko Urano Art Unit : Unknown
Serial No. : 10/574,194 Examiner : Unknown
Filed : March 28, 2006 Conf. No. : 9270
Title : METHODS FOR DIAGNOSING AND TREATING ENDOPLASMIC
RETICULUM (ER) STRESS DISEASES

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

December 20, 2006
Date of Deposit

Mary J. Zyzanski
Signature

Mary J. Zyzanski
Typed or Printed Name of Person Signing Certificate

Applicant : Fumihiko Urano
Serial No. : 10/574,194
Filed : March 28, 2006
Page : 2 of 2


Attorney's Docket No.: 07917-259US1 / (UMMC 04-
35 and 05-07)

Please apply any charges or credits to Deposit Account No. 06-1050, referencing
Attorney Docket No. 07917-259US1.

Respectfully submitted,

Date: _____


Dec. 19, 2006



Janice Kugler DeYoung
Reg. No. 50,429

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906
21515915.doc

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-259US1	Application No.
		Applicant Fumihiko Urano	
	Filing Date	Group Art Unit	



U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	6,531,292	03/11/03	Jasper D. Rine et al			
	A2						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	B1							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	C1	Bays et al., "Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation," Nat. Cell. Biol. 3(1):24-9 (2001)
	C2	Calton et al., "IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA," Nature 415(6867):92-6 (2002)
	C3	Chau et al., "A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein," Science 243(4898):1576-83 (1989)
	C4	Deak and Wolf, "Membrane Topology and Function of Der3/Hrd1p as a Ubiquitin-Protein Ligase (E3) Involved in Endoplasmic Reticulum Degradation," J. Biol. Chem., 276(14):10663-10669 (2001)
	C5	Finley et al., "Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant," Mol. Cell. Biol. 14(8):5501-9 (1994)
	C6	Fonseca et al., "WFS1 Is a Novel Component of the Unfolded Protein Response and Maintains Homeostasis of the Endoplasmic Reticulum in Pancreatic β -Cells," J. Biol. Chem. 280(47): 39609-615 (2005)
	C7	Harding et al., "Transcriptional and translational control in the Mammalian unfolded protein response," Annu. Rev. Cell Dev. Biol. 18:575-99 (2002)
	C8	Hosokawa et al., "A novel ER alpha-mannosidase-like protein accelerates ER-associated degradation," EMBO Rep. 2(5):415-22 (2001)
	C9	Hosokawa et al., "Enhancement of endoplasmic reticulum (ER) degradation of misfolded Null Hong Kong alpha1-antitrypsin by human ER mannosidase I," J. Biol. Chem. 278(28):26287-94 (2003)
	C10	Iwawaki et al., "A transgenic mouse model for monitoring endoplasmic reticulum stress," Nat. Med., 10(1): 98-102 (2004)
	C11	Kaneko et al., "Human HRD1 protects against ER stress-induced apoptosis through ER-associated degradation," FEBS Lett. 532(1-2):147-52 (2002)
	C12	Kaufman et al. "The unfolded protein response in nutrient sensing and differentiation," Nat. Rev. Mol. Cell. Biol. 3(6):411-21 (2002)
	C13	Kayo and Koizumi, "Mapping of murine diabetogenic gene mody on chromosome 7 at D7Mit258 and its involvement in pancreatic islet and beta cell development during the perinatal period," J. Clin. Invest. 101(10):2112-8 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-259US1	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Fumihiko Urano	
		Filing Date	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	C14	Kikkert et al., "Human HRD1 Is an E3 Ubiquitin Ligase Involved in Degradation of Proteins from the Endoplasmic Reticulum," J. Biol. Chem., 279(5):3525-534 (2004)
	C15	Kopito and Ron, "Conformational Disease," Nat. Cell Biol., 2:E207-E209 (2000)
	C16	Kpriyanov et al., "Generation of Recombinant Antibodies," Molecular Biotechnology, 12:173-201 (1999)
	C17	Molinari et al., "Role of EDEM in the release of misfolded glycoproteins from the calnexin cycle," Science 299(5611):1397-400 (2003)
	C18	Mori, "Tripartite management of unfolded proteins in the endoplasmic reticulum," Cell 101(5):451-54 (2000)
	C19	Nadav et al., "A novel mammalian endoplasmic reticulum ubiquitin ligase homologous to the yeast Hrd1," Biochem. Biophys. Res. Commun. 303(1):91-7 (2003)
	C20	Nishitoh et al., "ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats," Genes Dev. 16(11):1345-55 (2002)
	C21	Oda et al., "EDEM as an acceptor of terminally misfolded glycoproteins released from calnexin," Science 299(5611):1394-7 (2003)
	C22	Oyadomari et al., "Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes," J. Clin. Invest. 109(4):525-32 (2002)
	C23	Özcan et al., "Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes," Science 306:457-461 (2004)
	C24	Patil and Walter, "Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals," Curr. Opin. Cell Biol. 13(3):349-55 (2001)
	C25	Shamu and Walter, "Oligomerization and phosphorylation of the Ire1p kinase during intracellular signaling from the endoplasmic reticulum to the nucleus," EMBO J. 15(12):3028-39 (1996)
	C26	Soto, "Protein misfolding and disease; protein refolding and therapy," FEBS Lett. 498(2-3):204-207 (2001)
	C27	Tirasophon et al., "A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells," Genes Dev. 12(12):1812-24 (1998)
	C28	Urano et al., "Coupling of Stress in the ER to Activation of JNK Protein Kinases by Transmembrane Protein Kinase IRE1," Science, 287:664-66 (2000)
	C29	Yoshida et al., "A time-dependent phase shift in the mammalian unfolded protein response," Dev. Cell 4(2):265-71 (2003)
	C30	Yoshida et al., "XBP1 mRNA is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor," Cell 107:881-91 (2001)
	C31	Yoshioka et al., "A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice," Diabetes 46(5):887-94 (1997)
	C32	Zinszner et al., "CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum," Genes Dev. 12:982-85 (1998)
	C33	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	